That’s because the purpose of a science fair is to celebrate discovery. But here’s the problem. Sometimes we manage research departments the same way.

Universities and corporations employ extraordinarily talented researchers, occupy expensive laboratories, purchase specialized equipment and consume billions of dollars pursuing new ideas. In fiscal year 2024 alone, American universities reported $117.7 billion in research and development expenditures.

That is not a science fair. Its an industry. And perhaps we should start managing it like one.

The Difference Between Discovery and Impact

Research organizations are remarkably good at counting things.

Grant dollars, papers published, and patents applied for. Those large come from invention disclosures, departmental awards, and conference presentations. Things things matter. But none necessarily means that something useful happened.

A patent is not a product, just as a publication is not a customer, and a prototype is not manufacturing. A startup document doesn’t equal a company, and even a license agreement is really just somebody promising to try. The federal government recognized this distinction decades ago.

The policy behind the Bayh-Dole Act does not merely encourage universities to patent federally funded discoveries. It specifically talks about utilization, commercial collaboration and making inventions available to the public. In other words: Discovery isn’t the finish line.

Xerox Won the Science Fair

Few companies demonstrate this better than Xerox. At Xerox PARC, researchers helped create technologies that read like they accidentally discovered the next forty years of computing. Networked computers, graphical user interfaces (GUI), ethernet, and laser printers. If the goal had been to win the world’s greatest science fair, Xerox would need a larger trophy case.

The problem was what happened next.

Xerox struggled to convert many of those extraordinary inventions into businesses. Researchers could create astonishing prototypes. But they lacked an equally effective mechanism for deciding what should happen to these successful inventions afterward. The Xerox Alto is a perfect example.

Xerox demonstrated a computer in the 1970s containing many features we now associate with modern personal computing. But the company never successfully turned the Alto into a mass-market computer.

The lesson isn’t that Xerox executives were stupid. (Quite the contrary.) Xerox successfully commercialized some PARC technologies, (most notably laser printing), and research inevitably produces ideas that don’t fit the company creating them.

The point is that invention and commercialization are different capabilities. Xerox had built an extraordinary invention machine. It had not built an equally extraordinary conversion machine.

Kodak Invented Its Own Replacement

Kodak provides an even more fascinating example. In 1975, Kodak engineer Steven Sasson built one of the earliest self-contained digital cameras. Think about that for a moment.

Kodak didn’t miss digital photography - it largely invented it. The research department had done exactly what a great research department was supposed to do. Unfortunately, the invention threatened the business Kodak already had. Kodak made money selling film, photographic paper and chemicals.

Digital photography potentially eliminated much of that ecosystem. So the problem wasn’t technological. It was economic. Kodak created the future while enjoying enormous financial incentives to protect the past. That’s why commercialization cannot simply begin when somebody hands a patent disclosure to a technology-transfer office.

The potential consequences of an invention need to be considered while the research portfolio is still being managed. Sometimes the most valuable discovery reinforces an existing business. Sometimes it destroys one. Sometimes it requires a completely different customer.

Or manufacturing process. Or distribution system. Or business model. Or company. Research management should be designed to recognize the difference.

The Laboratory Has Customers

Calling research a business does not mean every laboratory needs to produce quarterly profits. It means recognizing that research has customers—even when those customers aren’t obvious yet. For a university, those customers might ultimately be companies, patients, government agencies, manufacturers, entrepreneurs or communities.

The return might be a drug, or a software platform, or a manufacturing process. That could mean a startup, a standard, or maybe a license. Or perhaps knowledge that enables somebody else to build something valuable. But somewhere inside the research organization there needs to be a theory of conversion.

Money and talent go into one end, knowledge comes out the other. Then what?

Which discoveries deserve more investment? Which need customer discovery? Which require regulatory expertise? Which should be patented? Which belong in startups? Which should be licensed? Which should be released openly?

And perhaps most importantly, which should stop? Businesses call this portfolio management. Research organizations sometimes find that conversation uncomfortable.

Stop Measuring the Parade

Universities naturally celebrate what is easiest to count. Grant awards make wonderful press releases.

So do patents, startups, and big checks. Commercialization is much messier. It can take years. Outside companies become involved. Markets change. Technologies fail. One successful therapy or manufacturing process may create more impact than hundreds of projects that never leave the laboratory.

That doesn’t mean we shouldn’t measure commercialization. It means we should measure the pipeline rather than the parade. Imagine looking at research as a funnel. At the top are research expenditures, projects and discoveries.

Then come validated problems, prototypes, disclosures and protectable intellectual property. Farther down are industry collaborations, licenses, startups and follow-on investment. At the bottom are products, services, treatments, manufacturing processes and measurable public benefits.

Most projects shouldn’t make it through. That’s fine. Good businesses kill weak projects too. The important thing is understanding why projects disappear from the funnel, and making sure the strongest ones move forward deliberately rather than accidentally.

Build the Conversion Machine

Universities already possess most of the pieces. Research administration, sponsored programs, industry engagement, and technology transfer. Then there’s entrepreneurship, economic development, faculty expertise, students, and labs, What we often don’t have is a system connecting them early enough.

Too often, technology transfer enters the process after the research decisions have been made, the grant money has been spent, the graduate students have graduated, and somebody has dismantled the prototype. Then a disclosure arrives. “Here’s what we invented.” And the commercialization team is expected to find somebody who wants it.

Now imagine reversing that. Researchers would still decide what questions deserve investigation. Basic research would remain basic research. Academic freedom would remain academic freedom. But researchers could gain earlier access to information about unmet needs, industry problems, regulatory pathways, manufacturing challenges, potential partners and startup capital.

Research leadership, meanwhile, could see which types of projects actually move from discovery to use. That feedback loop might change everything.

What Happens After the Ribbon?

There is nothing wrong with a science fair. They create curiosity, celebrate experimentation, and encourage people to show each other something interesting. Universities should probably do more of that. They simply shouldn’t confuse the fair with the enterprise.

The morning after the symposium, somebody needs to ask, ‘What happens next? Is there a customer? A licensee? A manufacturer? A startup? A clinical pathway? Does the project need more development? Or has it reached the end of the road?

Xerox showed us that an organization can invent the future and still fail to capture much of it. Kodak showed us something even stranger. An organization can help invent the future, and then discover that the future threatens the business it already has.

The lesson isn’t that research should become less adventurous. It’s almost the opposite. If we’re going to spend billions of dollars searching for extraordinary discoveries, we should build equally extraordinary systems for recognizing what happens when we find one.

The ribbon celebrates the discovery. The Big Idea is building what comes next.

Swift could still own or control rights in the underlying songs, but the familiar recordings themselves were another piece of property entirely. The U.S. Copyright Office explains that a musical composition and a sound recording are separate copyrighted works, often owned and licensed separately. So Swift found the seam between them and pried it wide open in a way nobody had ever done before.

She announced that she would simply record her songs again. New performances, therefore new sound recordings, resulting in new masters for the same songs. Radio stations and streaming companies that wanted her support would have to use the new recordings. The strategy became the Taylor’s Version project; re-recorded albums she released between 2021 and 2023.

But here is the question: What if somebody had patented that idea?

Not Taylor Swift. The idea.

A while back, I wrote about a patent application that came uncomfortably close to this neighborhood. Music financier David Pullman, (best known for the so-called Bowie Bonds), pursued a continuation application, U.S. Patent Application No. 16/574,328, directed to creating a pool of intellectual-property assets for securitization.

The timing was curious. Swift publicly discussed re-recording in the summer of 2019. Pullman filed the continuation in September. The application claimed priority through a chain reaching back to 2002. In my original AIPLA article I wondered whether the suddenly valuable idea of replacing old masters with newly created ones might have been somewhere in the strategic background.

There is no evidence that Pullman actually tried to patent “Taylor’s Version,” and his claim was not written that way. The interesting part is the missed idea hiding beside the application: Could someone have patented a repeatable business process for using newly created masters to alter the economics of an older catalog?

The Patent That Wasn’t

A patent cannot simply claim, “Artist dislikes record deal, artist re-records album, artist makes more money.” Patent law is not a reservation system for clever business ideas. Under 35 U.S.C. § 101 and current USPTO guidance, claims directed merely to abstract ideas, (including many methods of organizing human activity), often fail eligibility unless the claim as a whole adds something more.

But imagine the filing in 2002, before streaming remade the industry. The applicant does not try to patent singing the songs again. Instead, the claims describe a system: Identify a catalog whose original sound recordings are controlled by another party; determine when contractual re-recording restrictions expire; create replacement masters; register and distribute those new recordings; redirect licensing opportunities toward the replacements; bundle the resulting royalty streams; and use the new catalog to change the economic value of the old one.

Now it starts sounding less like revenge and more like a method.

Would it have survived examination? Maybe not. Novelty, obviousness, written description and patent eligibility would all have been serious hurdles. And today’s eligibility framework is especially unforgiving toward claims that amount to a business strategy performed with generic technology. The USPTO itself notes that business methods are not categorically excluded, but they still must clear the judicial exceptions governing abstract ideas.

Still, that is what makes this a Missed Idea. The question is not whether a broad patent on re-recording music should have issued. The question is whether somebody, early enough, could have recognized that the valuable invention was not the new recording, but instead the economic architecture around it.

The Invisible Asset

Swift demonstrated something the music business had largely treated as a contract footnote: a re-recording right can become a strategic asset. A new master does more than create another copy of a song. It can create a competing asset that is controlled by the artist. Fans can choose it. Streaming can favor it. Film, television and advertising licensors can potentially choose it. And every dollar flowing toward the replacement affects the bargaining power surrounding the original.

That is the invisible economy underneath Taylor’s Version. Copyright supplied the raw material. Contract law supplied the timing. Brand loyalty supplied the demand. Distribution platforms supplied the scale. The innovation was seeing those pieces as a system.

Swift later wrote that the success of the Taylor’s Version albums and The Eras Tour helped make it possible for her to buy back her music. In 2025, she announced that she had ultimately purchased her original masters outright. She said the saga had changed contract negotiations for younger artists, with new artists telling her they negotiated to own their masters. Her strategy did not merely produce replacement albums. It changed what artists knew to ask for. Her own account of it all is here.

And That May Be the Bigger Miss

Patents expire. Contract language evolves. Business models get copied. The most valuable ideas sometimes escape protection because nobody recognizes what they are until everyone can see them.

Pullman’s ’328 application was rejected, appealed, and ultimately abandoned. My earlier article followed that strange patent trail because its 2002 priority claim seemed to reach into a music economy that did not yet exist. But the more interesting possibility is the claim nobody appears to have owned; the deliberate conversion of an artist’s re-recording right into a mechanism for shifting licensing demand, catalog value and negotiating leverage.

Taylor Swift did not need that patent. She had something better: Taylor Swift.

For everybody else though, the lesson is worth remembering. When an industry-changing strategy looks obvious in hindsight, there was usually a moment when it wasn’t.

That is where patents live.

Patents got claims. Trademarks got registrations. Copyrights got ownership analyses. Trade secrets got locked doors and nondisclosure agreements. Data got a sentence, if anything at all.

Sponsored research agreements gave companies rights in “results.” Technology licenses tossed “data” into a broadly ill-defined description of technical information. If somebody wanted a dataset, we negotiated confidentiality, security, permitted use, deletion and (if we were feeling particularly ambitious) what happened to derivatives. That worked fine when the data was mostly evidence behind a research paper.

Then AI showed up.

An Asset Without a Comfortable IP Box

Corporations, universities and medical centers now possess enormous collections of clinical records, images, genomic information, sensor readings, materials data, financial information and research observations. AI has made many of those collections dramatically more valuable.

The problem is that data doesn’t fit comfortably inside the traditional IP boxes.

Facts themselves are not generally protected by copyright, although the selection or arrangement of a database may be. Trade-secrets can protect valuable compilations, but secrecy matters. Research funders may require data sharing. Human-subject data bring privacy and consent obligations. And once a university gives a company a copy, much of the institution’s remaining control comes from the contract.

The strange thing is that the company may never have needed the copy in the first place.

The Question Behind the Data

Imagine a university medical center with fifteen years of patient information. A pharmaceutical company wants the dataset to determine which patients respond best to a cancer treatment. The instinctive licensing question is: What should we charge for the data?

Try a different question. Why does the company need the data?

It probably doesn’t want to read 300,000 patient records. It wants to know which biomarkers correlate with their treatment response? Which combinations of medications produce better outcomes? Which patients belong in the next clinical trial?

Those are not possession questions. They are computation questions. That is where homomorphic encryption gets interesting.

The Library Behind Opaque Glass

Normal encryption is terrific while data are stored or traveling between systems. The awkward moment traditionally comes when somebody wants to use them. The information gets decrypted, a calculation occurs, and the result gets encrypted again.

Homomorphic encryption changes that. NIST describes fully homomorphic encryption as a way to compute functions over encrypted data without knowing the secret key. The computation happens while the information remains encrypted. Think of a rare manuscript in a library.

Traditional data licensing is like letting a researcher photocopy the manuscript and take it home. The contract can say what the researcher may do with the copy. But the researcher has the copy.

Homomorphic encryption is closer to putting the manuscript behind opaque glass. The researcher submits a question. The system searches the manuscript. The researcher receives the authorized answer. But the manuscript never leaves the vault.

That small distinction could create an entirely different IP business model. Instead of licensing a dataset, a university could license permission to ask the dataset questions.

The agreement might define the permitted computation, the authorized output, the field of use, the number of queries, the records or cohorts that may be analyzed, whether model training is permitted, who owns a resulting model, and whether a competitor may ask different questions of the same underlying data.

Termination changes too.

Traditional data licenses eventually contain some version of delete all copies. Then everybody hopes they did. A computational license can simply stop answering queries after a certain date. Revocation becomes technical instead of aspirational.

Healthcare and Banking

Healthcare seems almost designed for this application. The data are extraordinarily valuable and equally difficult to share.

Researchers increasingly are demonstrating that privacy-preserving computation can work across decentralized health information. A 2025 NPJ Digital Medicine study used homomorphic encryption in a decentralized clinical-analysis framework involving an international influenza cohort and U.S. COVID-19 mortality data. A 2026 study applied multiparty homomorphic encryption to federated survival analysis.

The solution isn’t one giant medical database. It instead likely to be hundreds of databases capable of computing together without surrendering their underlying patient records.

Now imagine a criminal moving money through five banks. Nothing at Bank A looks particularly alarming. Neither does Bank B. The pattern appears only when the transactions are viewed together. The obvious answer is to combine the information. The equally obvious problem is that banks cannot casually hand one another their customer records.

Mastercard tested a different approach through Singapore’s privacy-enhancing technology sandbox. Its proof of concept used fully homomorphic encryption to explore sharing financial-crime intelligence across Singapore, the United States, India and the United Kingdom.

Again, the important thing was not sharing the database. It was sharing the computation.

There Is No Magic Here

Homomorphic encryption is not a privacy wand.

It can be computationally expensive. Existing software may have to be redesigned. Key management matters. Outputs themselves can leak information. Ask a medical database a sufficiently narrow question and the answer may identify someone even if the cryptography worked perfectly.

That is why NIST treats FHE as one member of a larger privacy-enhancing toolkit alongside technologies such as multiparty computation, private set intersection and zero-knowledge proofs. Sometimes a secure enclave, federated architecture, differential privacy or another approach will be cheaper or better. The point is not that every dataset should be homomorphically encrypted. The point is that we should stop assuming every valuable use of data requires handing someone the data. That matters for technology transfer.

The Next IP

A university could potentially license oncology computations to one company, cardiovascular analytics to another and device-performance analysis to a third. Exclusivity could be assigned to a field, cohort, query or commercial application instead of the entire dataset. The same information could generate recurring commercial value without ten companies walking away with ten copies.

That changes valuation. It changes exclusivity, cybersecurity, and termination. And it changes what we mean when we call data an IP asset. For decades, we tried to write better contracts controlling what companies may do after we give them data. Perhaps the more interesting solution is to stop giving it to them.

1. Let them ask the question.

2. Let the encrypted data do the work.

3. Give them the answer.

4. Keep the asset.

The next generation of data licensing may not license data at all; it may instead license computation.

You know the machine. A stuffed animal sits six inches from the prize chute. You line up the claw perfectly. You press the button. The metal fingers descend, close around the toy, lift it toward freedom, and then, (almost insultingly), let go.

The bear falls back into the pile and you walk away. That was the business model. Or at least it seemed to be. The claw machine was a little box of frustration wedged between skee-ball and the exit. Nobody built a Saturday night around it.

They do now.

The Wall Street Journal recently chronicled the rise of dedicated “clawcades”, storefronts filled almost entirely with claw machines, glowing under neon lights and stocked not with anonymous stuffed animals but instead with recognizable characters, collectibles and, (occasionally), luxury goods. CoStar reports these businesses are moving out of niche Asian shopping districts and into mainstream American malls and shopping centers.

The strange part is that nothing about the machine itself is new; but the business model around it is.

Winning Changed

The old claw-machine operator had a simple precept; make the prize difficult to win. Every toy that stayed inside the cabinet protected the margin. The new operators discovered something more valuable than the toy - the return visit.

CommonWealth Magazine documented this transformation in Taiwan, where large claw arcades started replacing cheap plush with snacks, drinks and even household goods. More importantly, operators made the machines easier. The goal shifted from squeezing maximum margin from a single prize to creating high turnover, visible winners and an atmosphere in which people believed they could actually succeed.

The old model monetized failure, the new one monetizes return. That sounds like a small adjustment, but it’s not. It many ways it is borrowing some of concepts that built Las Vegas.

A customer who loses ten times and leaves angry may have produced a profitable transaction. A customer who wins twice, posts the third attempt to TikTok, then trades two prizes toward a larger one and comes back next weekend is an asset.

The Prize Changed, Too

And this is where the invisible economy starts to appear.

A generic teddy bear has manufacturing cost, shipping cost and retail value. Pikachu has all of those things plus intellectual property. So does an anime figure, a designer toy, or a character that somebody has spent years turning into a tiny emotional shortcut.

Bandai Spirits does not treat crane-game merchandise as leftover inventory. Its Banpresto operation plans prizes specifically for amusement facilities, emphasizes the “worlds” of the underlying IP, and commercializes more than 1,800 figures and premium products annually. In a separate history of its World Collectable Figure line, Bandai Spirits describes a deliberate effort to make the prize itself the reason people came to the arcade.

That is an amazing reversal. The game used to make the prize interesting; now the prize makes the game interesting. And because licensed characters arrive with built-in fandom, the operator no longer has to create desire from scratch. The character did that years ago. The clawcade simply places a game between desire and possession.

The IP Is Not in the Claw

Anyone can buy machines, lease a storefront, and fill a room with LED lights. If the category keeps growing, all three will become commodities. The defensible business sits outside the cabinet.

It is the trademark on the door. The visual identity of the room. The licensed characters inside the machines. The exclusive prize arrangements competitors cannot duplicate. The operating know-how governing prize cost and win frequency. The customer data showing which machine gets played, which prize moves, how long someone stays and what makes them return. It is the trade-up system, the loyalty program, the vendor relationships and eventually, the franchise manual.

And perhaps, one day, it is a character the clawcade owns itself.

Pop Mart’s filings show what ownership can look like at scale. In 2025, 99.1% of its revenue came from proprietary products, with artist IPs including THE MONSTERS, MOLLY, SKULLPANDA and CRYBABY driving the overwhelming majority. Labubu did not become valuable because plastic suddenly improved. It became valuable because a character became a world, and the world became demand.

A smart clawcade operator should understand that.

The Customer Became the Advertising

There is another reason this works today that would have been nearly useless twenty years ago; the transaction is camera-ready.

A claw attempt has suspense, movement, a near-miss and a reveal, usually in less than thirty seconds. It requires no explanation. The viewer knows exactly what is supposed to happen. So the customer does something unusual - they record the purchase.

Nobody films themselves taking a sweater to the register at Macy’s. People absolutely film a claw hovering over the one plush they have been chasing for the past twenty minutes. That turns the store into a studio, the prize into a prop and the customer into a media channel. The better operators are not simply designing for foot traffic. They are designing for the phone pointed through the glass.

What Comes Next

Round1’s 2025 integrated report says demand for crane games has grown in both Japan and the United States, helped in America by larger prize lineups, large-format machines, popular Japanese characters and a growing embrace of Japanese culture. The interesting question is no longer whether the claw can support a store as much as what the store becomes next.

Imagine a clawcade with memberships. Limited-edition drops. Exclusive character collaborations. Inter-store tournaments. Now throw in QR or NFC-authenticated prizes., digital collections tied to physical wins, and special creator nights. A loyalty app that knows what you collect. Trade-ups across locations. A house mascot that begins as a plush prize, moves into animation and apparel, and eventually gets licensed to somebody else.

At that point, the company is no longer operating claw machines. It is using claw machines as a distribution system for IP (their own as well as other creators). The entrepreneur who owns forty machines owns forty depreciating assets. The entrepreneur who builds a recognizable clawcade brand owns something better. The entrepreneur who eventually creates the character everybody comes in to win may own something better still.

The machine is visible, as is the prize. But the real business is what you cannot see through the glass.

Peptides sat in the middle; chains of amino acids capable of recognizing biological targets with remarkable precision, but generally too fragile for the stomach’s chemical cauldron and too large to easily slip through cell membranes. So we injected them.

Insulin made that bargain famous more than a century ago and the history of insulin is really the first chapter of the peptide economy. Modern GLP-1 drugs have made it spectacularly profitable. Then something changed; not with the biology, but with the engineering.

The Wall Street Journal pointed past the wellness-clinic fascination with injectable “peptides” and toward a much more consequential story: companies learning how to make peptide medicines as pills. It sounds like a formulation improvement, but it’s not. It is more akin to figuring out how to land airplanes on water; bringing an entire category of new destinations within reach.

Consider psoriasis. For years, some of the most effective targeted medicines for serious inflammatory disease have been powerful antibodies that usually must be injected. Protagonist Therapeutics built a peptide-discovery platform around the idea that a much smaller molecule might deliver biologic-like precision while behaving more like a conventional drug.

That work produced icotrokinra, an oral peptide that blocks the IL-23 receptor. In March 2026, Johnson & Johnson announced FDA approval of ICOTYDEfor moderate-to-severe plaque psoriasis. A targeted peptide had crossed one of the field’s most formidable borders from injection to pill.

Two months later, the same idea appeared in a completely different disease. PCSK9 is a proven cholesterol target, but the blockbuster drugs that inhibit it have historically been injectable antibodies. Merck developed enlicitide, a macrocyclic peptide engineered into a ring-shaped structure, and in July 2026 the FDA approved LIPFENDRA, the first approved oral PCSK9 inhibitor. The important word is not cholesterol. It is oral.

Peptides are becoming a programmable middle layer between traditional drug classes. Small molecules can be wonderfully convenient, but many biological surfaces are simply too broad or complicated to grab effectively. Antibodies can bind those surfaces beautifully, but they are large, expensive to manufacture and generally can’t be swallowed.

Macrocyclic and engineered peptides merge these worlds: enough surface area and structural complexity to engage difficult targets, yet enough chemical tunability to improve stability, permeability and, in selected cases, oral delivery. Nature Chemical Biology has already demonstrated cyclic-peptide discovery workflows that simultaneously screen for target activity and permeability, exactly the combination that used to make oral peptides feel contradictory.

And that changes where the IP lives. A conventional view says the asset is the molecule. Patent the sequence, the composition, or the therapeutic use. But the emerging peptide stack is much deeper. The valuable IP can also sit in the screening library that found the molecule, the chemical modifications that keep it from being chewed apart by enzymes, the macrocyclization strategy that locks it into the right shape, the formulation that helps it cross a membrane, the process that manufactures it at scale, and the data that teaches the next design which molecular compromises actually work.

Merck offers a particularly good example. Getting a complex macrocyclic peptide to work in a tablet is only half the problem. You also have to make millions of doses. In May, Merck scientists described a large-scale biocatalytic synthesis process for enlicitide using a tailored suite of enzymes. That is a reminder that the defensible asset may not be one patent sitting alone on the shelf. It may be an innovation catalog; molecule claims, process claims, platform know-how, analytical methods, manufacturing trade secrets and regulatory data all protecting the same commercial outcome.

The financial market has noticed. In 2024, Novartis agreed to a peptide-drug-conjugate collaboration with PeptiDream that carried up to $2.89 billion in potential value. In 2025, AstraZeneca signed a macrocyclic-peptide discovery agreement with Syneron Bio valued at up to $3.475 billion. Those numbers are not proof that every peptide platform will succeed. They are evidence that pharmaceutical giants can see peptide discovery itself, (the engine, not just the output), as licensable IP.

Artificial intelligence adds another layer. Peptide chemistry has always involved a brutal combinatorial problem - change one amino acid, close the ring differently, hide one hydrogen bond, add a non-natural residue, and the molecule may bind better while becoming impossible to absorb. Or, it may absorb beautifully and stop binding. Recent peptide research increasingly combines chemical synthesis with computational modeling and AI-guided design. Nature Reviews Chemistry described 2025 as a convergence of peptide chemistry and computational modeling. The molecule is becoming partially computational before it ever becomes physical.

That creates a fascinating ownership question. If the competitive advantage comes from a model trained on thousands or even millions of failed peptide designs, what is the real asset? The successful molecule? The training data? The screening protocol? The negative results nobody publishes? The algorithm that predicts permeability? The manufacturing recipe that makes the winning structure economical? The answer, increasingly, is ‘all of the above’.

There is also a caution hiding inside. “Peptides” now describes two very different markets. One is a regulated pharmaceutical race producing approved medicines and carefully characterized manufacturing processes. The other includes wellness and online sellers offering unapproved injectable compounds. In August 2026, FDA warning letters targeted sellers of products including semaglutide, tirzepatide, retatrutide and other peptides that the agency said were unapproved new drugs. The scientific opportunity is real, but so is the regulatory boundary.

Ironically, regulation may make the IP story even more interesting. In July 2026 the FDA issued 17 revised draft product-specific guidances for generic peptide products. As peptide medicines mature, innovators will face the same question every successful technology eventually faces; what remains proprietary when the original molecule gets competition? Expect the answer to move outward toward delivery, combinations, next-generation sequences, manufacturing efficiency, platform technology and the accumulated know-how required to make difficult peptides behave like easy drugs.

For a century, peptides were valuable despite their limitations. Now those limitations are becoming engineering problems. And engineering problems create IP. The next pharma land grab may not be over a single miracle molecule. It may be over the rules for designing an entire class of molecules that can reach antibody targets and that patients can swallow.

There was only one problem. Making a small sapphire cover for a fingerprint sensor and making millions of smartphone-sized pieces of sapphire are not the same thing. That difference, (between proving an innovation can work and proving it can work at scale), is where this story gets interesting.

Apple reached out to GT Advanced Technologies, a New Hampshire company with expertise in sapphire-growing equipment. GTAT’s Advanced Sapphire Furnace business had historically centered on selling equipment and technology to sapphire producers. GTAT’s historical strength was building and selling the ovens, but Apple was asking it to become the bakery. Then asking the bakery to feed one of the largest consumer-electronics production systems in the world.

The deal announced in late 2013 was enormous. Apple agreed to provide GTAT up to $578 million in four milestone-based prepayments. GT would use that money to build sapphire-growth capacity at a massive Apple-owned facility in Mesa, Arizona. The program ultimately contemplated 2,036 sapphire furnaces. The catch was hiding in plain sight: Apple’s money was an advance that GT had to repay, while the supply arrangement did not give GTAT the kind of guaranteed purchase volume that might normally protect a supplier making such a concentrated bet.

That matters because GTAT was not merely expanding an existing production line. It was trying to invent the production line while operating it.

The economics depended heavily on growing much larger sapphire boules than GTAT had previously demonstrated at commercial scale. Accounts of the bankruptcy record described the push toward roughly 262-kilogram boules and the difficulty of producing enough Apple-acceptable material from them. Bigger boules promised better economics because more usable sapphire could come from each furnace cycle. On a spreadsheet, that is the kind of improvement that makes a factory look brilliant. But physics doesn’t always follow spreadsheets.

A crystal can emerge from a furnace and still be economically useless. Cracks, defects, contamination, or inconsistent crystallization can turn hours of furnace time, electricity, raw material, and labor into scrap. GTAT’s own 2014 SEC filing reported significant sapphire ramp-up costs, inventory losses, and production inefficiencies while equipment and processes were still being qualified.

Read that sentence again. GTAT was establishing production processes inside a factory being built for volume production. Apple needed manufacturing, but GTAT was still doing development. Those two activities can look remarkably similar right up until the invoices arrive.

And growing the crystal was only half the problem. A sapphire boule still had to be sliced, ground, polished, finished, inspected, and converted into something Apple could actually install in a device. Bankruptcy-era accounts described serious fabrication and cost problems in addition to the crystal-growth difficulties. So GTAT had problems at both ends: growing enough acceptable sapphire and economically turning it into acceptable components.

But the most useful lesson is not about who was the villain. It is about scale.

Companies love the phrase “proof of concept.” It sounds reassuring. Something worked in the lab, the prototype performed, the patent was filed, and everyone starts talking about markets. But between a successful prototype and a successful product sits an entire second innovation system: manufacturing. Equipment reliability, cycle time, scrap, and supply chains. Then there is training, quality control, and Maintenance. Finally, there is finishing, inspection, and yield.

A prototype answers one question: Can we make it? A production line answers another: Can we make it profitably? A profitable production line answers the question that eventually matters most: Can we make it repeatedly, at specification, on schedule, at a cost somebody will pay? Those are different accomplishments. Apple and GTAT were trying to achieve all three almost at once.

Mesa magnified every uncertainty. The facility was roughly 1.3 million square feet. Furnaces were arriving. Employees were being hired. Fabrication equipment had to work. Power had to be reliable. Apple’s specifications had to be met. Cash was tied to milestones. Meanwhile, the manufacturing process itself was still moving underneath everyone’s feet.

By April 2014, the engineering problem became a financing problem. GTAT failed to satisfy technical requirements associated with Apple’s fourth prepayment; Apple withheld the final $139 million and obtained rights connected to repayment of earlier advances. That created the ugliest loop in advanced manufacturing: the factory needed cash to solve its technical problems, while the technical problems were preventing the factory from getting the cash.

In September, Apple introduced the iPhone 6 and iPhone 6 Plus without the anticipated GT sapphire display covers. On October 6, 2014, GT Advanced Technologies filed for Chapter 11 bankruptcy protection. Media reports described a stock collapse of more than 90 percent after the filing. Less than a year had passed since the Apple agreements were signed.

Bankruptcy then exposed how differently the two companies viewed what had happened. GTAT’s chief operating officer, Daniel Squiller, portrayed the Apple relationship as extraordinarily demanding and economically lopsided. Apple pushed back, emphasizing that GTAT was a sophisticated company that had negotiated and signed the agreements. Both points are worth keeping in the frame. Apple had extraordinary leverage. GTAT still chose to take the bet.

But the most useful lesson is not about who was the villain. It is about scale.

Companies love the phrase “proof of concept.” It sounds reassuring. Something worked in the lab, the prototype performed, the patent was filed, and everyone starts talking about markets. But between a successful prototype and a successful product sits an entire second innovation system: Manufacturing, equipment reliability, and cycle time. Then there’s scrap, supply chains, and training. Finally, there’s quality control, maintenance, and yield. Any one of which could the magic bullet that kills the entire thing.

Mesa tried to cross too many of those bridges at the same time. New boule size. New production operation. New fabrication process. New factory, workforce, and customer relationship. Huge volume. Aggressive schedule. And financing directly tied to technical milestones. Any one of those risks might have been manageable. Together they created a system with almost no room for failure.

The better path is much less glamorous. Build the pilot before the cathedral. Run 20 furnaces before 2,000. Learn what actually breaks. Measure first-pass yield instead of theoretical capacity. Calculate cost per acceptable finished component, not cost per furnace cycle. Create kill gates before everyone becomes emotionally and financially committed to the project. And when a supplier is being asked to carry frontier technical risk, structure the contract so the customer carries some of that uncertainty too.

That last point is important for university inventors and startups. A large customer can feel like validation, (and, sometimes, it is). But that one customer can become so important that it stops being a customer and becomes the business model. At that point, every technical delay is a financing issue, every specification change pushes your timeline out farther, and walking away becomes harder precisely when it may be necessary.

Sapphire itself was never a foolish idea. Apple had already demonstrated that sapphire made sense in smaller iPhone applications. The failure was assuming that because the material worked, the manufacturing system was ready to follow. It wasn’t.

That is the enduring image from Mesa; more than a million square feet of factory space, thousands of sophisticated furnaces, hundreds of millions of dollars, smart engineers, and one of the world’s most capable technology companies. All waiting for a manufacturing process to become something it had not yet become.

In 2018 Tesla went through what CEO Elon Musk called ‘production hell’, trying to scale production to where they could manufacture cars economically. When he announced the Model Y in 2019, he described “building the factory as a hundred times harder than building the car“.

There is a tendency to treat manufacturing as the boring part that happens after invention. Mesa teaches the opposite lesson. Sometimes manufacturing is the invention. Until you have invented that, you do not really have a product. You have a prototype and a very expensive plan.

The premise was almost aggressively simple. Someone hurts the wrong man. The wrong man turns out to be the worst possible man to hurt. But buried inside that familiar revenge story was the beginning of something far more valuable than a plot: a world. There was a mysterious hotel called the Continental. There were gold coins. There were rules. There was an unseen criminal order operating beneath ordinary society. The original screenplay was reportedly far more grounded than the movie that followed, but those little pieces of mythology were already there. They were the seeds of the IP.

Producer Basil Iwanyk and Thunder Road Pictures saw enough in Scorn to move quickly. Then Keanu Reeves read it. Reeves liked the character, but he also seems to have understood something important about the property: John Wick was more interesting than Scorn. In fact, Reeves kept referring to the project by the character’s name until everyone eventually surrendered. The title changed. A screenplay named for an emotion became a franchise named for a person.

Then the Stuntmen Got the Keys

The next transformation may have been even more important. Reeves took the script to Chad Stahelski and David Leitch, stunt veterans he knew from The Matrix. They were not merely interested in staging the action. They saw a mythology hiding behind it. Stahelski has described imagining the Continental as part of an underworld with the scale of Dante, secret societies, ritual, consequence, and rules. The gunfights would not simply interrupt the story. They would become part of the storytelling.

That distinction matters. Plenty of movies have assassins. Plenty have revenge. Plenty have expensive cars, tailored suits, martial arts and firearms. John Wick assembled those ingredients into a recognizable system. The choreography became a signature. The Continental became a place audiences wanted to visit. The coins became objects fans wanted to own. The High Table became an institution capable of generating stories without John Wick even being in the room. In IP terms, the movie stopped being a character plus a plot and became a platform.

It was not an obvious blockbuster. The first film cost roughly $20–30 million and earned about $86 million worldwide. Respectable, certainly. But the economics got better with every trip back to the Continental. Chapter 2 reached roughly $171 million worldwide. Chapter 3 climbed above $327 million. Chapter 4 became the franchise’s theatrical high-water mark at about $440 million according to Lionsgate. Four John Wick films crossed $1 billion in worldwide box office.

The Real Asset Was the World

The clever part is what happened around the movies. Lionsgate did not have to keep asking the same question — how many more times can John Wick shoot his way through another room? — because the filmmakers had accidentally built a universe with detachable parts. The Continental could become a television prequel. The Ruska Roma could support Ballerina. Caine, the blind assassin introduced in Chapter 4, could walk into his own story. Even a gold coin could leave the screen and become merchandise.

That is where the John Wick story becomes especially interesting as intellectual property. The valuable thing is no longer only copyright in four movies. It is the stack: copyrighted characters and stories; trademarks around the franchise and its branding; licensing rights for games, apparel and collectibles; recognizable trade dress and iconography; and a growing body of fictional institutions, customs and lore that can be recombined into new products. Lionsgate’s merchandising program has stretched into figures, apparel, statues and replicas. The franchise even entered gaming early through a Payday 2 collaboration and later John Wick Hex.

There is also a useful warning hidden in Hex. The game was removed from digital storefronts after its license expired. That is IP in its least romantic form. A fictional assassin may be immortal. A license agreement is not. The ability to keep selling someone else’s universe lasts exactly as long as the contract says it does.

So What Comes Next?

The obvious answer is, more John Wick. But the more interesting answer is that Lionsgate no longer needs every John Wick product to be about John Wick. In 2024 the studio announced a Caine feature starring Donnie Yen, continuing the character’s story after Chapter 4. Lionsgate has also said another film following the events of Chapter 4 is in development. The franchise is becoming less like a film series and more like a fictional platform.

The strongest evidence may be the next video game. In February 2026, Lionsgate and Saber Interactive announced a new AAA John Wick game for PlayStation 5, Xbox Series X|S and PC. Keanu Reeves and Chad Stahelski are involved, and the game is not simply replaying one of the films. It is being built as an original story set years before Wick’s ‘Impossible Task.’ That matters because it treats the franchise’s timeline itself as licensable creative territory.

And that may be the future of John Wick, not Chapters 5, 6 and 7 until Reeves needs a walker with a gun rack. The more durable strategy is to keep opening doors inside the world: the High Table, the Continental network, the adjudicators, the Ruska Roma, Caine, earlier chapters in Wick’s career, perhaps stories in cities where John Wick never appears at all. The IP can expand sideways instead of merely forward.

There is a nice irony in all of this. John Wick is a story about a man desperately trying to get out. The intellectual property built around him keeps finding ways to pull him back in. Derek Kolstad started with a revenge script called Scorn, Reeves gave it a better name, then Stahelski and Leitch gave it a visual language. Thunder Road and Lionsgate gave it scale. Audiences gave it value. Somewhere along the way, the deadliest man in the room became something even harder to kill: A franchise!

Merck had not invented it. Merck had acquired a company, that had acquired a company, that invented it! The molecule had changed corporate parents, changed internal identification numbers, and nearly changed owners again. Today, we know it as Keytruda. That makes the beginning difficult to reconcile with the ending. Because it’s origin story begins with a brake.

The immune system is remarkably good at finding things that do not belong; viruses, bacteria, and other abnormal cells. But an immune system that attacks everything would be almost as bad as the threats it is designed to stop. So the body also has mechanisms that tell immune cells when to stand down. One of those mechanisms involves a protein called PD-1.

PD-1 sits on certain immune cells, including T cells. When it receives the proper signal from proteins such as PD-L1, the T cell reduces its activity. Think of a security guard at a locked door. Someone approaches and so the guard prepares to intervene. When a visitor produces the correct credential, the guard steps aside. Cancer figured out how to manufacture that credential.

Many tumors exploit this checkpoint, effectively telling the immune system, “Nothing to see here.” Pembrolizumab (the molecule that became Keytruda) blocks PD-1 and interrupts that conversation. It does not attack the tumor in the way legacy chemotherapies do. It removes one of the brakes that prevents the immune system from attacking it. The science behind that idea came from years of basic research.

Tasuku Honjo and his colleagues identified PD-1 in the early 1990s, and helped establish its role as an immune regulator. James Allison pursued another checkpoint, CTLA-4. Their work on negative immune regulation ultimately earned Honjo and Allison the 2018 Nobel Prize in Physiology or Medicine. What began as basic research into how the immune system regulates itself was becoming an entirely new way to treat cancer.

But the antibody that became Keytruda did not begin at Merck. It originated at Organon, a Dutch pharmaceutical company, where Gregory Carven, Hans van Eenennaam, Gradus Dulos and colleagues worked to create antibodies capable of binding to human PD-1. That IP trail is unusually clear: the Organon patent family identifies Carven, van Eenennaam and Dulos as inventors on antibodies directed to the human PD-1 receptor. Their work produced the antibody that would eventually become pembrolizumab. But then the ownership of it started moving.

Schering-Plough acquired Organon BioSciences in 2007. Pembrolizumab came with the portfolio. In 2009, Merck completed its roughly $41 billion merger with Schering-Plough and inherited the antibody. (Nobody spent $41 billion to buy Keytruda. That is the fascinating IP lesson. More on that in a bit.)

Acquisitions are usually valued around things everyone can see: Revenue, products, market share, manufacturing, distribution, and promising late-stage pipeline assets. But intellectual property can hide inside a transaction like a mineral deposit beneath a farm. Yes, the buyer purchases it. But the buyer doesn’t always understand what it now owns.

After the merger, Merck had to understand its much larger research portfolio. Experimental drugs compete for money, scientists, clinical resources, and years of development. Pembrolizumab was still largely a promise. The program fell to low priority and came close to being licensed away before Merck reactivated it and shifted toward human testing.

The first-in-human study, KEYNOTE-001, began in 2011. Competition also helped change the context. Bristol Myers Squibb was moving aggressively into immune checkpoints with drugs that became Yervoy and Opdivo. Suddenly, Merck was not evaluating an obscure inherited antibody in isolation. A competitor was spending serious money to validate the category. The molecule had not changed, but the market had.

KEYNOTE-001 became far larger than a conventional Phase I study as researchers kept finding reasons to ask additional questions. More patients were enrolled. More cancers were tested. Dosing, biomarkers, previous treatments, and responses were explored. The study also produced important evidence in non-small-cell lung cancer; the 2015 New England Journal of Medicine report described pembrolizumab activity and the relationship between PD-L1 expression and treatment response.

Merck’s attention to PD-L1 as a biomarker was strategically important. Rather than pretending the drug would work equally well for everyone, researchers tried to identify tumors more likely to respond to PD-1 blockade. A smaller target population could produce clearer evidence, stronger results, and a faster regulatory path. Then the results began turning an inherited research asset into a franchise.

In January 2013, pembrolizumab received FDA Breakthrough Therapy designation. On September 4, 2014, the FDA granted accelerated approval to Keytruda for certain patients with unresectable or metastatic melanoma whose disease had progressed after prior therapy. It was the first FDA-approved anti-PD-1 therapy in the United States. Melanoma proved the concept, but lung cancer changed the scale.

Keytruda moved into non-small-cell lung cancer, then into first-line treatment and combinations with chemotherapy. Merck expanded development across cancers, treatment stages, biomarkers, and drug combinations. At that point, it morphed from a single drug and started behaving like a platform.

Its reach now is remarkable. The current FDA prescribing information spans melanoma, non-small-cell lung cancer, head and neck cancer, classical Hodgkin lymphoma, urothelial cancer, colorectal cancer, gastric and gastroesophageal cancers, cervical cancer, renal-cell carcinoma, endometrial carcinoma, triple-negative breast cancer, esophageal cancer, cutaneous squamous-cell carcinoma and other settings with specific biomarkers, treatment combinations, or stages of disease.

Perhaps the clearest sign that something had changed came in 2017. The FDA approved pembrolizumab for certain tumors where the cells cannot correctly fix DNA copying errors, (leading to a high number of mutations). The National Cancer Institute described it as the first FDA approval of a cancer treatment based on a tumor’s genetic characteristics regardless of where in the body the cancer originated. For generations, oncology organized cancer by anatomy: Lung, colon, breast, or skin. Keytruda helped present a different idea; that the mechanism meant more than its mailing address on the body.

Keytruda’s IP story was equally complicated. Merck owned the antibody, but it did not own every important right surrounding PD-1 cancer treatment. Bristol Myers Squibb and Ono Pharmaceutical asserted patents involving the use of anti-PD-1 antibodies to treat cancer. In 2017, Merck settled the worldwide patent litigation, paying $625 million upfront and agreeing to royalties of 6.5 percent through 2023 and 2.5 percent from 2024 through 2026.

That is what real commercialization often looks like. A blockbuster does not always emerge from a perfectly fenced estate of patents owned by one company. Valuable technologies can sit inside overlapping rights. Sometimes the objective is not to own everything. It is to own enough, (and secure access to the rest), to build the business.

By 2025, Keytruda and Keytruda Qlex generated approximately $31.7 billion in worldwide sales. Merck’s SEC filing shows how extraordinary the transformation had become: one molecule inherited through an acquisition had grown into the company’s dominant oncology franchise. And then the story approaches another IP turn.

Keytruda’s exclusivity won’t last forever. Merck has told investors that biosimilar competition in the United States could begin in December 2028, when the primary compound patent expires. Two related composition-of-matter patents extend into 2029, and litigation could affect the exact timing. But 2028 is when Merck expects the U.S. franchise could begin facing biosimilar competition.

That creates an almost perfect closing chapter to the IP story. A molecule that began as a piece of Organon intellectual property, traveled through two acquisitions, nearly lost its place in a corporate portfolio, survived a major patent dispute, and became one of the world’s most commercially important medicines is now approaching the bargain built into the patent system itself.

Patents are temporary, but the knowledge they contain is not. Keytruda began as scientific insight into an immune-system brake. Organon turned that insight into an antibody, Schering-Plough acquired Organon, and then Merck acquired Schering-Plough. The molecule survived long enough for clinical evidence to catch up with the idea, and then accumulated uses one cancer at a time.

One indication became several. A drug became a platform. An inherited piece of intellectual property became a $30-billion-a-year franchise. And in 2028, the protection that helped make that investment possible begins giving way to the next stage of the story. Success makes history look inevitable. But Keytruda was anything but inevitable. Merck didn’t simply commercialize a remarkable drug. It learned, (just in time), what it owned.

This story has a particular resonance for me. My father missed out on Keytruda by only a few months, his small cell lung cancer getting diagnosed in April 2015 and he was gone in July . I miss him every day, but I take comfort that many other patients now have a treatment option he never had.

They unlock hotel rooms. They open park entrances. They pay for lunch. They summon photographs from roller coasters. They glow during fireworks. They vibrate during interactive adventures. They have become so commonplace that most guests barely notice them. That is usually the fate of great innovation. Once it becomes indispensable, it becomes invisible.

Long before the MagicBand became a symbol of the modern Disney experience, undergraduate engineering students at the University of Florida were given what appeared to be an ordinary capstone assignment. Design a wearable hardware device. They returned the following semester and developed software to go with their new gizmo.

At first glance, it looked like any other sponsored design project, the kind completed every year by engineering students across America. In retrospect, it became something else. It became a reminder to corporate America that universities don’t simply produce graduates. They can produce incredibly profitable devices.

Universities measure themselves by the number of students they educate, the papers they publish, and the research dollars they attract. Industry measures success differently. Companies ask whether a new idea reduces costs, increases revenue, or creates an entirely new market. Sponsored engineering programs occupy the rare space where both worlds overlap. Students receive an education. Companies receive fresh thinking. Occasionally, both receive something neither expected.

The MagicBand illustrates what happens when those incentives align.

Undergrad Prototyping

The idea for the band was conceived by a Disney executive reading a SkyMall catalog on a flight, where he spotted a golf tracker wristband and thought it would be a good concept to include as part of their “Next Generation” project. So, he approached the University of Florida’s Herbert Wertheim College of Engineering.

The Integrated Product & Process Design (IPPD) program is an experiential two-semester capstone course where multidisciplinary student teams design, build, and test prototypes for industrial sponsors. The program has existed for twenty-five years and is one of the most popular classes in the college.

The initial tasking was in 2009, comprising of instructions to “Design a customer-facing location-aware mobile device application designed to enhance park guest experience.” The initial prototype was big, bulky, and not something a customer would want to wear, much less wear it while walking through a theme park. But it was, after all, a prototype. Executives decided to see what the students could do next.

Undergraduate engineering students.

The following semester the students were invited to take their prototype and “Implement a system that provides an interactive guest information system built into the tabletop at a food & beverage restaurant location and supports theme park information, menu info, and personal guest info, (Photopass, Fastpass).” The student’s demonstrated several concepts that executives agreed would enhance the customer experience.

By the time Disney introduced the MagicBand to guests in 2013 as the centerpiece of the MyMagic+ ecosystem, the wristband had evolved far beyond a simple wearable device. It had become the physical interface to an entirely new operating system for Walt Disney World.

One piece of technology now replaced paper tickets, hotel room keys, credit cards, FastPass reservations, PhotoPass cards, dining confirmations, and countless other fragments of the guest experience. With a simple tap of the wrist, the entire vacation became connected. Disney wasn’t merely simplifying admission into its parks. It was redesigning how guests interacted with every aspect of the resort. Many observers focused on the wristband itself. Strategically, that was the least interesting part of the innovation.

Marketing materials developed by Disney.

The real innovation was the invisible systems behind it. Every interaction generated data. Every attraction visited, every restaurant selected, every purchase completed, every photograph taken, every hotel door opened, every queue entered, and every pathway traveled quietly became another data point. Disney had not simply created a wearable device. It now has a digital twin of the guest’s entire visit. That changes everything.

For decades, theme parks operated much like shopping malls. Managers could estimate attendance and revenue, but they understood relatively little about how individuals or families moved through the environment. The MagicBand transformed that uncertainty into measurable intelligence. Disney could study guest behavior with a level of precision previously reserved for digital companies.

Amazon could observe what customers clicked. Netflix could observe what subscribers watched. Spotify could observe what listeners played. Disney could now see how families physically experienced a destination measured in thousands of acres. With Magic Bands, movement through the park became a digital information source.

The brilliance of the system was that guests experienced it as a convenience rather than surveillance. Every eliminated inconvenience made the vacation feel more magical. Every magical moment generated another stream of behavioral insight. The better the experience became, the more valuable the underlying data became. Customer satisfaction and operational intelligence reinforced one another in a continuous feedback loop.

That is not a wearable. That is a platform.

Design 2.0, 3.0, 4.0, ...

Some people will read this and think a bunch of students took away jobs from designers working for local companies, or even Disney itself. Quite the opposite is true. A small engineering class in Gainesville, Florida created new work for designers, developers, and engineers (literally) across the country.

At the beginning, MagicBands cost more than $35 each just to make them. The original design was contracted out to one of the more famous specialty design companies, called Frog. Designers there worked with the legendary team of Disney Imagineers to come up with a final design that dropped the price down to only $5 each.

The design of the electronics was done by Synapse Product Development in Seattle, WA, a long-established engineering developer for Disney. The wearables are made from Thermoplastic Polyurethane (TPU), a protein free hypoallergenic that holds up well to water, sunscreen, and the wide-ranging scented menagerie people frequently have on their skin while vacationing.

A handful of the many prototype MagicBands Disney developed.

The job of connecting the devices to the various connections throughout the Disney parks fell to Level 11, also out of Seattle. Their software development ensured data was collected, stored, and ultimately analyzed to provide the decision-making support the corporation was looking for to maximize the customer’s experience.

Jabil Circuit, out of St. Petersburg, FL was retained to manufacture the MagicBands at scale. Jabil is the second largest contract electronics manufacturer in the world, building components, systems, and final assembly products for global brands including Apple, GoPro, and Cisco.

Jabil’s Global Headquarters & Innovation Labs in St Pete, FL

The Disney Design Group in Orlando, Florida handled much of the art and design for the customized MagicBands featuring Disney, as well as other company’s trademarked characters, franchises, and other intellectual properties.

Disney created numerous specialized MagicBands for various franchises.

Disney is a company that takes its packaging more seriously than most companies, and it retained InFold, Ltd, in Rhode Island to create the foundation for how customers would first encounter the MagicBand.

The Platform

The evolution of the MagicBand demonstrates a principle that universities rarely teach explicitly: successful products almost never stop evolving after launch. The original MagicBand authenticated customer identity, enabled payments, opened hotel rooms, and simplified access throughout the resort. Later generations expanded the platform even further.

MagicBand+ introduced rechargeable electronics, lighting, vibration, gesture recognition, and interactive experiences that allowed the wristband itself to participate in attractions, nighttime spectaculars, and immersive storytelling. The hardware had quietly become another Disney character.

Even more interesting was the commercialization strategy surrounding the product.

Initially, the wristband functioned as infrastructure. Eventually, it became merchandise.

Disney’s extraordinary portfolio of intellectual property transformed a functional device into a collectible product line.

Guests could purchase designs featuring Marvel superheroes, Pixar characters, Frozen, Toy Story, Haunted Mansion, Disney Villains, seasonal celebrations, anniversary editions, and countless limited releases. The underlying electronics changed very little. The intellectual property layered on top of them changed constantly.

One manufacturing platform suddenly supported hundreds of retail products, each carrying its own emotional appeal while sharing nearly identical production economics. The wristband itself became another licensing canvas. This is where the engineering story becomes a business story.

Too often universities evaluate sponsored projects by asking whether a prototype worked. Industry asks a much more interesting question. Did the prototype become a platform? A prototype solves one problem. A platform enables hundreds of future solutions.

Viewed through that lens, the MagicBand represents something far larger than a successful engineering project. It illustrates how a multidisciplinary student experience can contribute to a commercial ecosystem that continues generating value years after graduation.

Industrial designers refine the human experience. Manufacturers optimize production. Software developers expand capabilities. Intellectual property transforms functionality into emotional connection. Data scientists improve operations. Marketing creates demand. Finance scales the model. Every discipline compounds the work of the one before it.

Innovation is rarely an individual achievement. It is usually a relay race.

For IP managers, that may be the most important lesson. The purpose of sponsored research projects is not merely to help students graduate. It is to expose them to problems significant enough that solving them changes the trajectory of an organization. Occasionally, those organizations are one of the most successful entertainment companies in the world.

But more often sponsoring companies are startups, regional manufacturers, hospitals, utilities, or nonprofit organizations. The size of the sponsor matters less than the quality of the problem. Students remember projects. Companies remember students. More importantly, companies get to know students beyond simply a name on a resume. By being involved in these projects they can see which students are a good cultural fit for their company. That reduces turnover, which saves money!

If the story of the MagicBand teaches us anything, it is this: The most valuable outcome of an engineering course is not the grade. It is the possibility that an idea born in a classroom can reshape an entire market. Every sponsored project contains that potential. Most never realize it. But the few that do become case studies. Corporate managers should consider how this low-cost initiative paid off.

Each of the two semesters at UF cost Disney $15,000. With over 40,000,000 MagicBands sold that is over one billion dollars in follow on revenue - not park tickets, not hotel rentals or food purchases, not even merchandise. A billion dollars in top line additional revenue - from a bunch of undergrad engineering students in a capstone class.

From a business standpoint, this is a terrific idea. Golfers spend years dreaming about famous holes they may never get to play. Tour 18 asked a simple question: what experience do customers already want, but find difficult or expensive to reach? So it brought the experience to them. The owners of Pebble Beach and other famous courses were less enthusiastic. Litigation followed, built largely around trademarks, trade dress and unfair competition. The courts could protect names, source-identifying features and, in some circumstances, distinctive trade dress. But the larger question remained; can anyone own the design of a place?

In 2024, Representatives Brian Fitzpatrick (Republican, PA) and Jimmy Panetta (Democrat, CA) introduced the BIRDIE Act; Bolstering Intellectual Rights against Digital Infringement Enhancement. The proposal would have amended the Copyright Act’s definition of an architectural work to include golf-course designs and features such as greens, tees, bunkers, lakes, paths, landscaping and topography. The American Society of Golf Course Architects backed it, arguing that simulators and video games shouldn’t reproduce a designer’s work without compensating the creator. The 2024 bill has not moved beyond Committee discussion, but that may be the least interesting thing about it.

The BIRDIE Act matters because golf is merely the easiest place to see a much larger collision coming. American intellectual-property law is very good at protecting things we can identify: inventions, books, songs, movies, brands, software and buildings. Architecture itself did not receive its modern copyright protection until the 1990 Architectural Works Copyright Protection Act. But what if the value is not a single object? What if the asset is an experience created by arranging things in an extraordinary place?

Nobody owns grass, sand or water any more than a novelist owns words or a composer owns musical notes. Creativity lives in composition. A novel guides your imagination one page at a time, just as a song guides emotion one measure at a time. A golf course guides decisions one shot at a time. Every bunker creates tension. Every dogleg withholds information. Every green asks a question that was not obvious from the tee. The golfer supplies the performance, but the architect wrote the stage directions.

That is why the old Tour 18 dispute matters. The course was not merely copying dirt; it was borrowing accumulated meaning. Pebble Beach is valuable partly because of geometry, but also because of sequence, context and memory. Move the eighteenth hole to the second and something changes. Remove the Pacific Ocean and something changes again. Erase decades of championships, famous shots and Sunday-afternoon television, and something else disappears. Same grass, but not the same asset.

This is where “experience” begins behaving like intellectual property. Consider Augusta National’s Amen Corner. Its power does not reside solely in three golf holes. It comes from where they occur in the round, what the player has already survived, what the player knows is at stake, and what can still go wrong. Move Amen Corner elsewhere and you have preserved the physical ingredients while damaging the narrative. Sequence carries value.

Disney understands this instinctively. Visitors do not enter the Magic Kingdom through Space Mountain. They arrive on Main Street, see Cinderella Castle, and then move outward into distinct lands. A museum does the same thing. So does a university campus, a Formula One circuit, and a luxury hotel,. These are not simply collections of physical assets. They are intentionally arranged journeys. The dirt, bricks and drywall are necessary. But they are not sufficient in and of themselves.

For most of history, geography protected these experiences for us. If you wanted to walk through the Louvre, you went to Paris. If you wanted to stand at the Grand Canyon, you went to Arizona. If you wanted Pebble Beach, you needed a tee time, an airline ticket and a willingness to open your wallet. Distance created scarcity, and scarcity created value. Then places became files.

Laser scanning, photogrammetry, drones, digital twins, game engines, virtual reality and generative AI are steadily separating experience from geography. A digital Pebble Beach can be stored, transmitted, modified, versioned and shared. It can reproduce today’s course or recreate an earlier version. It can change weather, green speed or pin placement. Eventually it may let four friends in four cities play the same authenticated course together - the game may be digital, but the friendships, memories, and experience are real.

At that point, the simulator is no longer merely a substitute for golf. It becomes a platform for a different experience built around the same place. Spotify did not eliminate concerts just as television did not destroy the Masters. Digital access often increases desire for the physical original. The hierarchy simply changes. The digital experience becomes discovery; the physical experience becomes pilgrimage. The bigger question is who controls the bridge between the two?

Imagine opening an app and finding five versions of Augusta National: Augusta Prime, Augusta Pro, Augusta 4K, Augusta Championship and Augusta Legends. All have five-star reviews. Only one is authorized. Which one is real? Counterfeiting is usually described as a product problem, but underneath it is an information problem. Buyers need to know whether something is what it claims to be. The better the copies become, the more valuable certainty becomes. A counterfeit does not merely copy the product. It taxes trust.

That same problem will impact digital places. An unofficial digital museum can improve the lighting, remove the crowds and add an AI guide who speaks every language. A virtual golf course can make the greens friendlier. A digital campus can combine Harvard-looking buildings, Stanford weather and MIT-style laboratories into a university that never existed. The copy may be more attractive than the reality. It may even be more fun. But once the copy begins shaping customer expectations about the original, the owner has more than a copyright problem. It has a brand-management problem.

Generative AI makes the issue harder still because customers will not merely consume these places. They will remix them. Ask a future golf engine for Pebble Beach’s ocean views, Augusta’s fairways and Pinehurst’s greens, and it may generate a beautiful course that doesn’t copy a single hole but instead borrows the design language of all three. Who authored that experience? The user who asked for it, the software company, or the architects whose work supplied the data for the Large Language Models? We are moving from licensing copies to licensing future possibilities.

That creates a new management problem I think of as the experience portfolio. Companies already manage patents, trademarks, copyrights, trade secrets, data and brands. They should begin inventorying authored experiences as well. Which physical or digital experiences are distinctive? Which depend on sequence? Which carry reputation or memory? Which can be digitized? Which should be widely distributed because abundance creates demand, and which should remain scarce because scarcity is part of the value?

The answer will not always be “lock it down.” Copying can educate, preserve and expand access. A digital Yellowstone can teach children who may never visit the park. A virtual museum can reach people who cannot travel. A simulator can introduce a golfer to a course they later decide to visit in person. The goal is not to stop reproduction. It is to build a framework for attribution, authenticity, and responsibility before somebody else builds the market around you.

This also explains why the economics extend well beyond the owner of the experience. A famous place creates a halo. Airports, hotels, restaurants, bartenders, retailers, drivers and local governments all participate. Augusta, Georgia changes during Masters week. New Orleans changes during Mardi Gras. If digital participation becomes a complement, the audience grows. If it becomes a substitute, value migrates. And value has a nasty habit of settling around whoever controls the customer relationship, the data and the payment.

That is the real lesson hiding inside the BIRDIE Act. The bill sounded almost quaint: should golf-course architects receive copyright protection when their courses are reproduced in simulators and video games? The larger question is what happens when places become software and experiences become portable.

Do not wait for Congress to tell you an experience is valuable. Law usually arrives after markets have already demonstrated the value. Look around your organization instead. What experience has been intentionally authored there? What part of it could be scanned, simulated, generated or copied? What would remain distinctive if the physical location disappeared? What should be licensed, authenticated or protected before someone else makes it portable?

The BIRDIE Act began with eighteen holes of golf. The bigger opportunity is recognizing the emerging intellectual property of place, sequence and experience. We spent the last century learning how to protect what people make. The next one may force us to decide how to protect where people go - and what happens to them when they get there.

Music may be the clearest example. At twenty, a song seems to explain the world. At forty, it begins explaining our relationships. At sixty, we realize it may have been explaining us all along. Certain songs become mirrors. We approach them at different stages of life and each time they introduce us to someone new.

When Metallica released The Unforgiven in 1991, listeners heard a song about anger, expectation, and the struggle to become one’s own person. Six years later James Hetfield returned to the title with The Unforgiven II. Eleven years after that, he returned again. I once assumed he was revisiting a successful idea. Now I suspect he was returning to a question that had never stopped asking him for an answer.

We all carry questions that refuse to disappear. They surface in different careers, different relationships, disappointments, and victories. We imagine we are starting over, when perhaps we are simply returning to conversations that have been waiting for us to catch up.

The Question Behind the Songs

Writers have a habit of spending their careers rewriting the same story. The characters change. The settings move. The conflict becomes more sophisticated. Somewhere underneath, however, the same question keeps resurfacing. Songwriters are no different.

Bruce Springsteen has spent much of his career writing about ordinary people struggling against circumstances they did not create. Johnny Cash returned repeatedly to themes of guilt, grace, and redemption. Bob Dylan explores identity and reinvention from so many different angles that his career almost defies chronological organization. While the melodies changed and the lyrics evolved, each artist quietly continued a conversation that had begun years earlier.

At first glance, The Unforgiven appears to be another song about authority. Listeners hear references to childhood, conformity, discipline, and emotional restraint. It is tempting to conclude that the song’s conflict lies between an individual and the institutions attempting to shape him.

How do we become the person others expect us to be without losing the person we were meant to become? In Metallica’s early work, authority usually lived outside the individual. Governments lied, courts failed, and military leaders sacrificed young soldiers. Someone else possessed power.

The Unforgiven quietly turned that camera around. Its deeper conflict is not merely that families, religions, and cultures impose expectations. It is that, eventually, we learn to impose those expectations upon ourselves. In that sense, the prison described throughout The Unforgiven is unlike the prisons that appeared in many earlier Metallica songs. It is not built of concrete or steel. There are no guards standing watch and no razor wire preventing escape. Every prison needs a warden. Sometimes that warden is the prisoner, because those doors are locked from the inside.

That may explain how the song reached listeners well beyond Metallica’s traditional audience. A soldier could hear the pressures of military discipline. A parent could identify with inherited expectations passed unconsciously to the next generation. A recovering addict hears the burden of shame. The song never insisted upon a single interpretation because it never acknowledged a single prison.

Learning the Language of Expectation

Expectations rarely arrive looking like prisons. They arrive as advice. Work hard. Respect authority. Make something of yourself. Parents and teachers usually mean well. That is precisely what gives expectation its power. The strongest cages are sometimes built by people who believe they are helping.

James Hetfield’s childhood reflected that paradox in ways both ordinary and extraordinary. Like countless families, his parents wanted what they believed was best for their children. Yet those beliefs were shaped by circumstances that Hetfield himself had not chosen.

His father left the family while James was still young, leaving his mother, Cynthia, to raise the children within the traditions of Christian Science. That faith would ultimately shape the defining tragedy of his adolescence. When Cynthia developed cancer, conventional medical treatment was never pursued because it conflicted with deeply held religious convictions. James was only sixteen when she died.

Moments like these have a way of reorganizing a person’s understanding of the world. They divide life into a clear “before” and “after.” Looking backward, we instinctively search for explanations. If nature abhors a vacuum, human nature truly despises it. We assemble a narrative explaining not only what happened, but why.

Listening to Metallica’s first four studio albums, it is easy to conclude that Hetfield’s anger was directed almost entirely outward. The institutions changed from one record to the next, but they remained the focus of the narrative. The young James Hetfield appeared to have little patience for organizations that demanded conformity while failing to earn trust.

Yet something subtle was lurking beneath the surface of those songs. The questions were changing. Ride the Lightning asked what powerful institutions might do to ordinary people. Master of Puppets explored the nature of control itself, whether imposed through addiction, manipulation, or fear. ...And Justice for All questioned whether justice could ever be truly impartial.

Each successive album peeled away another layer of so-called certainty. The villains became less obvious. The answers were less satisfying. Without announcing it, James Hetfield was gradually shifting his attention from external systems to internal struggles.

By the time Metallica released ReLoad in 1997, the band itself was living inside a different set of expectations. It had become one of the largest rock acts in the world, while changing its sound, appearance, and creative direction. Fans argued over whether the band was evolving or abandoning its roots. Into that argument came The Unforgiven II.

The decision was risky. Sequels invite comparisons that almost always favor the original. Every listener holds memories of the original song, making it nearly impossible for the second to be judged on its own merits. A sequel does not merely compete against other songs on the radio. It competes against nostalgia itself. That makes The Unforgiven II one of the most confident decisions Metallica ever made. Confidence, however, should not be mistaken for certainty.

There is a noticeable difference between the narrator of the two songs, and it has little to do with age. The voice that emerged in 1991 carried the frustration of someone struggling to understand how expectations had shaped his life. Anger remained close to the surface, but it had become reflective rather than explosive.

By the time The Unforgiven II appeared, something more subtle had occurred. The narrator no longer seemed interested in identifying who was responsible for the prison. Instead, he had begun asking whether escape was even possible.

Legally, the songs are separate works: different recordings, different copyrights, different moments fixed in time. Emotionally, they refuse to remain separate. The second song changes how we hear the first because the storyteller has changed. A movie sequel expands a narrative. The Unforgiven II expands a consciousness. That may be the trilogy’s most overlooked achievement.

The Silence Between the Songs

Between the second and third songs, Metallica entered one of the most turbulent periods in its history. The documentary Some Kind of Monster captured a band confronting creative conflict, group therapy, the departure of Jason Newsted, and Hetfield’s treatment for alcohol addiction. From the outside, Metallica looked invincible. From the inside, it was struggling to remain a band.

That gap was not an absence of creativity, but instead the presence of transformation. Hetfield has described songwriting as a process of discovery rather than declaration. Songs become a means of exploring emotions that resist ordinary conversation. Creative work frequently reveals thoughts that its creator has not yet organized into language.

Viewed through that lens, The Unforgiven II feels less like a sequel than a continuation of therapy. James Hetfield’s willingness to revisit his own emotional landscape suggests a songwriter less interested in defending his younger self than in understanding him. That is an extraordinarily vulnerable position for someone whose public image had long been built around confidence and aggression. Perhaps that is why The Unforgiven II initially puzzled so many listeners. They expected another chapter. Instead, they received a revision. Not of the song, but of the man who wrote it.

The Man in the Mirror

There is a curious moment that arrives in nearly every life. One morning we realize that the person we have spent years arguing with no longer exists. The angry young man is gone. The frightened child is gone. The ambitious twenty-five-year-old is gone. Only then do we notice how much of the argument was never with other people; it was with earlier versions of ourselves. That is why The Unforgiven III matters.

The certainty of the first song has faded. Even the searching quality of the second has changed. Reflection replaces accusation. The question is no longer simply who imposed the expectations, or who maintained them, but why they possessed such power in the first place.

Artists leave evidence of this evolution. Every album, novel, painting, or film preserves what its creator could see at one moment in time. The younger artist is not necessarily wrong. He is just incomplete. The older artist doesn’t need to erase him. He can answer him.

Perhaps that is what forgiveness sounds like. Not forgetting. Not excusing. Not pretending the pain never happened. Just refusing to let the youngest version of ourselves have the final word.

The James Hetfield of today would be unimaginable to the young man who wrote Kill ‘Em All. He is a husband, a father, a recovering alcoholic, and a musician whose influence stretches far beyond heavy metal. Millions admire him. Countless younger artists have built careers inspired by songs he has written.

Yet personal growth has an interesting habit of making certainty difficult to maintain. The older we become, the less interested we are in assigning blame. Life has a way of complicating every simple story.

The Song We Keep Rewriting

Most of us return to the same unresolved questions through different jobs, relationships, cities, and decades. We call them new problems because the scenery changed. Often, the lesson did not.

Business careers make the pattern easy to see. Early success is measured by growth, revenue, promotion, recognition. Later the questions change. What is enough? What was the point? What do I leave behind? Accomplishment gives way to contribution. Influence becomes more interesting than authority. The career we were building was quietly building us.

We also become unfair historians of our own lives. We judge decisions made with incomplete information using wisdom acquired years later. Yet we ask yesterday to defend itself using tomorrow’s evidence. No one could survive such a trial.

Perhaps maturity is not the accumulation of answers. Maybe it is becoming a kinder historian of our own life. That is why the stories that stay with us eventually stop being about the people who first told them. They become about us.

Somewhere along the way, I stopped hearing three songs and began hearing one life. The first voice spoke with certainty. The second began questioning that certainty. The third speaks more quietly because understanding rarely needs to raise its voice.

There are mistakes we regret, opportunities we missed, words we would choose differently. Beneath them stands the person we often judge most harshly: the younger version of ourselves. Forgiveness does not erase responsibility or rewrite history. It recognizes that growth depends on imperfect people learning from imperfect lives. Hetfield did something unusual in public: he let us watch him change.

In many ways, a new story began with The Unforgiven III. In 2017, Metallica created a nonprofit charity called All Within My Hands. A legendary heavy metal band known for aggression now invests in food banks, disaster relief, and workforce education. Its Metallica Scholars Initiative supports career and technical education through community colleges. Once trained, workers require tools and apparel, leading Metallica to craft partnerships with Lowes and Carhartt. That feels less like an unrelated final chapter than the natural conclusion of the conversation.

Making peace with the past has a way of changing what we do with the future. Maybe that is the quiet lesson hidden inside The Unforgiven. Grace is not merely something we receive from other people.

Sometimes it is what finally frees us to invest in someone else’s future.